149 related articles for article (PubMed ID: 688277)
1. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
Rose WC; Trader MW; Laster WR; Schabel FM
Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
[No Abstract] [Full Text] [Related]
2. Chronochemotherapy: L 1210 leukemia and beyond.
Halberg F; Nelson W; Cornélissen G; Haus E; Scheving LE; Good RA
Chronobiologia; 1979; 6(3):203-11. PubMed ID: 520097
[TBL] [Abstract][Full Text] [Related]
3. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
Schmid FA; Hutchison DJ
Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
[No Abstract] [Full Text] [Related]
4. Survival and cure of leukemic mice after circadian optimization of treatment with cyclophosphamide and 1-beta-D-arabinofuranosylcytosine.
Scheving LE; Burns ER; Pauly JE; Halberg F; Haus E
Cancer Res; 1977 Oct; 37(10):3648-55. PubMed ID: 908013
[TBL] [Abstract][Full Text] [Related]
5. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
[No Abstract] [Full Text] [Related]
6. Combined chronochemotherapy of L1210 leukemic mice using 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine, methylprednisolone and cis-diamminedichloroplatinum.
Scheving LE; Burns ER; Halberg F; Pauly JE
Chronobiologia; 1980; 7(1):33-40. PubMed ID: 7192203
[TBL] [Abstract][Full Text] [Related]
7. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
Burns ER; Scheving LE
Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
[No Abstract] [Full Text] [Related]
8. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
Shackney SE
Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
[No Abstract] [Full Text] [Related]
9. Single versus combination chemotherapy of L1210 leukemia.
Koza I; Balázová E; Ujházy V
Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
[TBL] [Abstract][Full Text] [Related]
10. [Selective treatment of leukemia L1210 with combination of deoxycytidine and lethal doses of cytosine arabinoside].
Bukhman VM; Lichinitser MR; Svet-Moldavskiĭ GIa; Mkheidze DM
Biull Eksp Biol Med; 1978 Mar; 85(3):340-3. PubMed ID: 276385
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
Avery TL; Roberts D
Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
[No Abstract] [Full Text] [Related]
12. Selective chemotherapy for advanced murine L 1210 leukemia by combination of 2' deoxycytidine and lethal doses of cytosine-arabinoside.
Buchman VM; Svet-Maoldavsky GJ; Lichinitser MR; Mkheidze DM
Biomedicine; 1977 Jul; 27(5):179-80. PubMed ID: 922116
[TBL] [Abstract][Full Text] [Related]
13. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide.
Scheving LE; Burns ER; Pauly JE; Halberg F
Cancer Res; 1980 May; 40(5):1511-5. PubMed ID: 7370988
[No Abstract] [Full Text] [Related]
14. Chronobiology as it relates to toxicology, pharmacology, and chemotherapy.
Scheving LE; Scheving LA; Feuers RJ; Tsai TH; Cope FO
Regul Toxicol Pharmacol; 1993 Apr; 17(2 Pt 1):209-18. PubMed ID: 8484028
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic performance of carminomycin-cyclophosphamide against L1210 leukemia.
Avery TL; Cruze PG
Cancer Res; 1978 Sep; 38(9):2892-5. PubMed ID: 679196
[No Abstract] [Full Text] [Related]
16. Cytosine arabinoside (NSC-63878)--clinical brochure.
Livingston RB; Carter SK
Cancer Chemother Rep 3; 1968 Dec; 1(1):179-205. PubMed ID: 4989814
[No Abstract] [Full Text] [Related]
17. Chemotherapy of leukemia L1210 in mice with 1-beta-d-arabinofuranosylcytosine hydrochloride. I. Influence of treatment schedules.
Kline I; Venditti JM; Tyrer DD; Goldin A
Cancer Res; 1966 May; 26(5):853-9. PubMed ID: 5936445
[No Abstract] [Full Text] [Related]
18. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
[No Abstract] [Full Text] [Related]
19. [Effect of combination chemotherapy of nitrosourea MCNU with various anti-tumor agents].
Ninomiya K; Sekido S; Araki T
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1315-23. PubMed ID: 6428326
[TBL] [Abstract][Full Text] [Related]
20. [Chronobiological aspects of experimental leukemia].
Ratte J; Haus E; Halberg F; Kühl JF; Shiotsuka R; Najarian JS
Union Med Can; 1974 Jul; 103(7):1201-7. PubMed ID: 4842174
[No Abstract] [Full Text] [Related]
[Next] [New Search]